Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma

Keyphrases

• Esophageal Squamous Cell Carcinoma 100%
• Pharmacotherapeutic Management 100%
• Causes of Mortality 33%
• Expert Opinion 33%
• Metastatic Disease 33%
• Targeted Therapy 33%
• Potential Biomarkers 33%
• Molecular Changes 33%
• Epidemiology 33%
• Nivolumab 33%
• Targeted Agents 33%
• Area Cover 33%
• Novel Treatments 33%
• Pembrolizumab 33%
• Esophageal Carcinoma 33%
• Esophageal Squamous Cell Cancer 33%
• Metastatic Setting 33%
• Novel Combinations 33%

Medicine and Dentistry

• Esophageal Squamous Cell Carcinoma 100%
• Malignant Neoplasm 50%
• Disease 50%
• Immunotherapy 50%
• Metastatic Carcinoma 50%
• Carcinoma 50%
• Biological Marker 50%
• Targeted Therapy 50%
• Cohort Effect 50%
• Nivolumab 50%
• Pembrolizumab 50%
• Esophagus Carcinoma 50%
• Immunotherapy Drug 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Esophageal Squamous Cell Carcinoma 100%
• Malignant Neoplasm 50%
• Disease 50%
• Biological Marker 50%
• Immunotherapy 50%
• Metastasis 50%
• Squamous Cell Carcinoma 50%
• Nivolumab 50%
• Pembrolizumab 50%
• Esophagus Carcinoma 50%
• Immunotherapy Drug 50%